Currency In USD
| Previous Close | 1.1 |
| Open | 1.09 |
| Day High | 1.19 |
| Day Low | 1.03 |
| 52-Week High | 2.66 |
| 52-Week Low | 0.86 |
| Volume | 2.94M |
| Average Volume | 1.21M |
| Market Cap | 163.17M |
| PE | -1.04 |
| EPS | -1.13 |
| Moving Average 50 Days | 1.56 |
| Moving Average 200 Days | 1.83 |
| Change | 0.08 |
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
GlobeNewswire Inc.
Feb 19, 2026 1:33 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
GlobeNewswire Inc.
Feb 19, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l
ALX Oncology Announces Pricing of Underwritten Offering
GlobeNewswire Inc.
Jan 30, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l